RIGEL PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.125 USD | +3.21% |
|
+1.82% | -22.76% |
Chart calendar Rigel Pharmaceuticals, Inc.
51.oWQebyFUGFXWDtzHIAeM_hrHX4_tLrxweMUg6-zdGuE.1hZuK3EXKg-0Rbe0WmXmzH6IGdyIfcooHoNVk6maIqXFUWQpQBVCBONWmQ~16aa1118291b1f3f90524da9c811f56e
Upcoming events on Rigel Pharmaceuticals, Inc.
Past events on Rigel Pharmaceuticals, Inc.
| 29/04/2024 | Q1 2024 Earnings Release (Projected) |
| 05/03/2024 21:30 | Q4 2023 Earnings Call |
| 05/03/2024 21:01 | Q4 2023 Earnings Release |
| 11/01/2024 20:00 | JPMorgan Healthcare Conference |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract No 2578 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract No 3247 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract No 2888 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Abstract No 1872 |
| 14/11/2023 15:30 | Jefferies London Healthcare Conference |
| 07/11/2023 21:30 | Q3 2023 Earnings Call |
| 07/11/2023 21:01 | Q3 2023 Earnings Release |
| 12/10/2023 16:15 | IDWeek Conference - Abstract #: 88 |
| 27/09/2023 20:35 | Cantor Global Healthcare Conference |
| 06/09/2023 | Citi BioPharma Conference |
| 06/09/2023 17:45 | Wells Fargo Healthcare Conference |
| 01/08/2023 21:30 | Q2 2023 Earnings Call |
| 01/08/2023 21:01 | Q2 2023 Earnings Release |
| 07/06/2023 19:30 | Jefferies Global Healthcare Conference |
| 05/06/2023 14:00 | American Society of Clinical Oncology Conference - Abstract No: TPS7085 |
| 25/05/2023 15:30 | Annual General Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 59,3 58,8 0.81% | 109 109 0.06% | 149 150 -0.4% | 120 93,2 29.01% | 117 115 2.04% | 149 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -28,3 -25,1 -12.62% | -7,81 -10,8 27.6% | -53,2 -90,9 41.47% | -19,3 -21,5 10.53% | -14,2 |
|
EBIT Million USD | Released Forecast Spread | -69,1 -72,9 5.19% | -29,0 -29,3 0.98% | -12,5 -13,3 6.03% | -55,6 -79,6 30.23% | -20,5 -25,3 19.04% | -11,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -66,9 -70,5 5.18% | -29,7 -29,5 -0.76% | -17,3 -17,0 -2.05% | -58,6 -80,5 27.26% | -25,1 -30,5 17.65% | -16,2 |
|
Net income Million USD | Released Forecast Spread | -66,9 -70,5 5.18% | -29,7 -29,5 -0.76% | -17,9 -17,6 -2.01% | -58,6 -80,5 27.27% | -25,1 -30,5 17.65% | -16,2 |
|
EPS USD | Released Forecast Spread | -0,40 -0,42 4.76% | -0,18 -0,17 -3.45% | -0,11 -0,10 -5.77% | -0,34 -0,46 26.09% | -0,14 -0,18 20.05% | -0,09 |
| Announcement Date | 27/02/20 | 02/03/21 | 01/03/22 | 07/03/23 | 05/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 20,4 21,2 -3.72% | 16,7 17,5 -4.61% | 29,8 23,7 26.06% | 46,6 39,2 18.69% | 22,4 22,6 -0.88% | 51,3 26,6 92.49% | 26,1 24,1 8.3% | 26,9 25,7 4.6% | 28,1 27,2 3.43% | 35,8 33,4 7.11% | 31,5 | 33,4 | 38,0 | 42,0 | 41,3 |
|
EBITDA Million USD | Released Forecast Spread | -17,5 -19,5 10.29% | -26,0 -19,5 -33.46% | -18,2 -20,6 11.83% | -12,4 -11,5 -7.55% | -4,97 -13,6 63.45% | -4,17 -10,6 60.63% | 2,26 0,44 417.69% | -3,86 | -3,76 | -7,58 | 1,04 | ||||
|
EBIT Million USD | Released Forecast Spread | -21,4 -23,3 7.91% | -26,3 -22,2 -18.48% | -13,0 -20,3 36.22% | -18,4 -22,0 16.2% | 2,08 -17,5 111.85% | -12,7 -17,1 25.77% | -5,27 -13,9 62.15% | -4,47 -11,4 60.68% | 1,97 -2,27 186.7% | -3,48 | -2,55 | -8,51 | 3,44 | -0,66 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -22,7 -22,4 -1.54% | -27,4 -23,2 -18.16% | -13,5 -21,6 37.66% | -19,0 -23,2 17.77% | 1,40 -18,5 107.56% | -13,5 -16,6 18.65% | -6,60 -14,6 54.87% | -5,69 -12,3 53.69% | 0,74 -4,17 117.67% | -4,68 | -4,00 | -8,78 | 1,26 | -1,10 | |
|
Net income Million USD | Released Forecast Spread | -22,6 -22,3 -1.45% | -27,4 -23,5 -16.65% | -13,5 -21,5 37.23% | -19,0 -22,9 16.9% | 1,40 -18,5 107.56% | -13,5 -16,6 18.65% | -6,60 -14,6 54.87% | -5,69 -12,3 53.69% | 0,74 -4,17 117.67% | -4,68 | -4,00 | -8,78 | 1,26 | -1,10 | |
|
EPS USD | Released Forecast Spread | -0,13 -0,13 -1.56% | -0,16 -0,14 -15.67% | -0,08 -0,12 35.13% | -0,11 -0,14 18.52% | 0,01 -0,10 110.17% | -0,08 -0,10 17.91% | -0,04 -0,08 48.74% | -0,03 -0,07 57.74% | 0,00 -0,02 - | -0,03 | -0,02 | -0,05 | 0,01 | 0,00 | |
| Announcement Date | 01/03/22 | 03/05/22 | 02/08/22 | 02/08/22 | 03/11/22 | 07/03/23 | 02/05/23 | 01/08/23 | 07/11/23 | 05/03/24 | - | - | - | - | - |
More events
Past sector events for Rigel Pharmaceuticals, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RIGL Stock
- Calendar Rigel Pharmaceuticals, Inc.
